News

But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...
Vinay Prasad, head of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA), ...
Loomer had slammed Prasad for allegedly denying drug approvals for rare diseases, and for his past support of left-leaning figures like Senator Bernie Sanders ...
The immediate ebullient reaction to Vinay Prasad’s ouster is understandable, and may ultimately be the correct one, Adam ...
Sarepta Therapeutics Inc. shares rose sharply early Tuesday after US regulators reversed course and recommended that patients ...
A top FDA appointee who doesn’t think patients can be trusted to make their own healthcare decisions.